Tonix Licenses Via-the-nose Treatment Technology From Inserm

Tonix Licenses Via-the-nose Treatment Technology From Inserm

286654

Tonix Licenses Via-the-nose Treatment Technology From Inserm

Tonix Pharmaceuticals has licensed technology from the French National Institute of Health and Medical Research (Inserm) that it aims to use for treating failure to thrive in Prader-Willi syndrome. The license will allow Tonix to expand its intranasal — administered via the nose — potentiated oxytocin program to a new indication, for PWS, the company said in a press release. Oxytocin is a hormone that helps to send signals within the brain. Sometimes called the…

You must be logged in to read/download the full post.